Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

Kailera Therapeutics licensed its portfolio of metabolic disorder drugs from Hengrui. The most advanced program has results from a Phase 2 test in China suggesting it could be competitive with ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Hengrui Pharma will receive an upfront payment of $200 million and is eligible to receive milestone payments up to $1.77 billion associated with certain development, regulatory and commercial ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.Most ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor camrelizumab can enter the U.S. market. The FDA has once again issued ...

Merck & Co. has entered a competitive race for a new type of heart drug, announcing Tuesday it will pay China-based Jiangsu Hengrui Pharmaceuticals $200 million upfront to license a pill that ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.